Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome
- 1 May 2013
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (5) , 782-783
Abstract
We have recently demonstrated that interleukin (IL)-22, mainly produced by T-helper 17 effector cells, natural killer (NK)p44+NK cells and epithelial cells, may be potentially involved in the pathogenesis of primary Sjogren's syndrome (pSS).1 The IL-22/IL-22R pathway is known to play a role in the emergence of T and B-cell lymphoma2 ,3 and pSS is considered a risk factor for the development of lymphoma.4 Rituximab, which has historically been used for the treatment of B-cell lymphoma,5 has also been considered to be effective in the therapy of pSS.6 Ten consecutive patients with pSS (eight women and two men, with a mean duration of disease of 48±18 months), diagnosed according to the American–European Consensus Group criteria for pSS,7 who were treated with two courses of intravenous infusions of 1000 mg rituximab (Roche, Woerden, The Netherlands) at days 1 and 15, at baseline and then after 6 months, were considered for this study. After 48 weeks the patients again underwent salivary gland biopsy. The demographic, clinical and histological characteristics of …Keywords
This publication has 9 references indexed in Scilit:
- Anti-CD20 Antibody Therapy for B-Cell LymphomasNew England Journal of Medicine, 2012
- Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndromeAnnals of the Rheumatic Diseases, 2012
- Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphomaNature Reviews Rheumatology, 2011
- The anti-CD20 antibody rituximab reduces the Th17 cell responseArthritis & Rheumatism, 2011
- Interleukin 22 Signaling Promotes Cell Growth in Mantle Cell LymphomaTranslational Oncology, 2011
- B‐cell targeted therapies in human autoimmune diseases: an updated perspectiveImmunological Reviews, 2010
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphomaLeukemia, 2008
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002